Buscar en
Radiología (English Edition)
Toda la web
Inicio Radiología (English Edition) Evaluation of central nervous system involvement in patients undergoing chimeric...
Journal Information
Share
Share
Download PDF
More article options
Visits
3
Brief report
Available online 1 December 2023
Evaluation of central nervous system involvement in patients undergoing chimeric antigen receptor-engineered T-cell therapy by magnetic resonance imaging
Evaluación mediante resonancia magnética de la afectación del sistema nervioso central en pacientes sometidos a terapia de células T con receptores quiméricos de antígenos
Visits
3
F.D. Choque-Cháveza,
Corresponding author
diegochoquechavez@gmail.com

Corresponding authors.
, A. Jareño-Badenasa,
Corresponding author
ajarenba95@gmail.com

Corresponding authors.
, D. Benítez-Ribasb, L. Oleagaa
a Departamento de Radiología, Hospital Clínic de Barcelona, Barcelona, Spain
b Inmunología, Hospital Clínic de Barcelona, Barcelona, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Abstract

Chimeric antigen receptor-engineered (CAR) T-cell therapy is an effective immunotherapy for aggressive hematologic cancers. However, it can lead to complications such as immune effector cell-associated neurotoxicity syndrome (ICANS), or complications related to the immunosuppressive status of these patients. The role of imaging in this context is essential to help in ICANS diagnosis and to rule out other potential diagnosis, such as central nervous system infections. Two cases are presented to illustrate this clinical problem.

Case 1

describes a 38-year-old patient with diffuse large B-cell lymphoma who developed ICANS after CAR T-cell therapy. MRI revealed signs of leukoencephalopathy. Case 2 involves a 57-year-old patient with mantle-cell lymphoma who presented neurologic symptoms -clinically suggestive of ICANS- after CAR-T therapy. MRI showed signs indicative of limbic encephalitis.

These two cases highlight the importance of MRI in clinical practice after CAR T-Cell Therapy underscoring the role of MRI in the diagnosis of complications in patients with neuropsychiatric symptoms.

Keywords:
CAR-T
ICANS
Lymphoma
Neurotoxicity syndromes
Immunotherapy
Immunosuppressed host
Resumen

La inmunoterapia de células T con Receptores Quiméricos de Antígenos (Chimeric Antigen Receptor-engineered T-cell, CAR-T) es efectiva en algunas neoplasias hematológicas, pero conlleva riesgos como el síndrome de neurotoxicidad asociado a células efectoras inmunitarias (Immune effector cell-associated neurotoxicity síndrome, ICANS), y otras complicaciones debido a la inmunosupresión. La resonancia magnética (RM) puede ayudar en el diagnóstico de ICANS y descartar otros diagnósticos como infecciones del sistema nervioso central. Se presentan dos casos para ilustrarlo.

Caso 1

paciente de 38 años con linfoma B difuso de células grandes que desarrolló ICANS posterapia CAR-T. La RM reveló signos de leucoencefalopatía. Caso 2: paciente de 57 años con linfoma de células del manto con síntomas neurológicos sugestivos de ICANS posterapia CAR-T. La RM mostró anomalías en el hipocampo lo que indica encefalitis límbica.

Estos casos resaltan la importancia de la RM después de la terapia con CAR-T y subrayan su papel en el diagnóstico de complicaciones en pacientes con síntomas neuropsiquiátricos.

Palabras clave:
CAR-T
ICANS
Linfoma
Síndrome de neurotoxicidad
Inmunoterapia
Inmunosupresión del receptor

Article

These are the options to access the full texts of the publication Radiología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.rxeng.2023.04.002
No mostrar más